4D Molecular Therapeutics, Inc.
FDMT
$14.34
-$0.29-1.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -33.44% | -43.33% | 139.05% | -29.73% | -56.38% |
| Total Depreciation and Amortization | 10.65% | 17.16% | 10.99% | 17.62% | 16.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.15% | -40.85% | -23.04% | -21.23% | 0.79% |
| Change in Net Operating Assets | -173.41% | 33.75% | 174.10% | -40.93% | 912.35% |
| Cash from Operations | -61.37% | -42.65% | 162.25% | -58.20% | -43.43% |
| Capital Expenditure | 16.67% | -- | 107.38% | 105.12% | 81.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 285.77% | 111.42% | -1,709.85% | -39.18% | 81.16% |
| Cash from Investing | 284.41% | 115.63% | -1,925.29% | -34.88% | 81.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,577.49% | -- | 18,532.61% | -79.58% | -95.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,811.72% | -- | 18,532.61% | -79.58% | -95.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.25% | 177.46% | 130.59% | -1,779.37% | 34.86% |